710

VAGINAL MICROBICIDE GEL FOR DELIVERY OF IQP-0528, A PYRIMIDINEDIONE ANALOG WITH A DUAL MECHANISM OF ACTION AGAINST HIV-1.

Mahalingam1, Simmons2, A.P., Ugaonkar2, S.R., Watson3, K.M., Dezzutti4, C.S., Rohan4, L.C., Buckheit3, Jr., R.W.  and Kiser1,2, P.F.  1Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah; 2Department of Bioengineering, University of Utah, Salt Lake City, Utah; 3ImQuest BioSciences, Inc., Frederick, Maryland; and 4Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, Pennsylvania.
Abstract

Pyrimidinediones, a novel class of compounds, have previously been shown to possess antiviral activity at nanomolar concentrations. One member of this class of compounds, IQP-0528, was selected as the lead molecule for formulation development owing to its stability at physiologically relevant conditions, wide therapeutic window, and antiviral activity in the nanomolar range. Here, we report the development of two vaginal gels—3.0% hydroxyethyl cellulose (HEC) formulation and a 0.65% Carbopol formulation—for the sustained delivery of IQP-0528. Stability studies under accelerated conditions confirmed the chemical stability of IQP-0528 and mechanical stability of the gel formulation for 3 months. In vitro release studies revealed that diffusion-controlled release of IQP-0528 occurred over 6 h, with an initial lag time of approximately 1 h. Based on the drug release profile, the 3.0% HEC gel was selected as the lead formulation for safety and activity evaluations. The in vitro and ex vivo safety evaluations showed no significant loss in cell viability or significant inflammatory response after treatment with a 3.0% HEC gel containing 0.25% IQP-0528. In an in vitro HIV-1 entry inhibition assay, the lead formulation showed an 50% effective concentration of 0.14 µg/ml for gel in culture media, which corresponds to ~0.001 µM IQP-0528. The antiviral activity was further confirmed by using polarized cervical explants, in which the formulation showed complete protection against HIV infection. In summary, these results are encouraging and warrant further evaluation of IQP-0528 gel formulations in in vivo models, as well as the development of alternative formulations for the delivery of IQP-0528 as a microbicide.

Keywords

Antiviral activity, Drug permeability, Drug uptake, IL-1α, IL-6, Interleukin-8 (IL-8), Tissue morphology, TNF-α, Trans-epithelial electrical resistance (TEER), Vaginal microbicide gel, VEC-100 tissue

Materials Tested

0.65% Carbopol, 1% Triton X-100, 3.0% hydroxyethyl cellulose (HEC), IQP-0528 a Pyrimidinedione analog, N-(2-Hydroxypropyl) methacrylamide polymer (pHPMA), Pyrimidinediones

Request a copy of this paper, click here.